Industry News
Pharmaceutical Industry News
With rates of colorectal cancer…
With rates of colorectal cancer surging among younger populations, Guardant Health is turning to a famous face beloved by Gen X and millennials to raise awareness of its screening test.
As more drugmakers begin to report…
As more drugmakers begin to report second-quarter earnings against the backdrop of the first material pharmaceutical tariff reveal from the Trump administration, Teva Pharmaceuticals isn’t sweating the situation.
Controversies, including a recent…
Controversies, including a recent regulatory tug-of-war with Sarepta and criticism from conservatives, marked Vinay Prasad's short tenure.
Daré Bioscience has started a…
Daré Bioscience has started a consumer awareness campaign to lay the foundations for the launch of its female sexual arousal drug, rolling out video and interactive content on a women’s health app.
Top F.D.A. Official Resigns Under Pressure
After turning down several new drugs and restricting use of another, Dr. Vinay Prasad drew the ire of the right-wing influencer Laura Loomer and others.
RFK Jr. Announces Plan to Restrict Opioid-Like Kratom Product
Federal officials said a psychoactive ingredient in kratom had been refined and added to supplements that could quickly become addictive.
Novo Nordisk, Ozempic Drugmaker, Sees Stock Plunge 20% After Profit Warning
Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.
In a phase 3 trial, the newest…
In a phase 3 trial, the newest Bruton’s tyrosine kinase (BTK) inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a head-to-head battle against the oldest treatment in the class, AbbVie and
AstraZeneca CEO Pascal Soriot said…
AstraZeneca CEO Pascal Soriot said the company has had many talks with the U.S. government and has proposed price reduction plans for its drugs.
After a first half that saw…
After a first half that saw Publicis Groupe snap up six companies around the world, the advertising giant is continuing its acquisitive streak with its first health-focused buyout of the year.
As part of a trade agreement…
As part of a trade agreement reached Sunday between the U.S. and the European Union, pharmaceutical imports—along with almost all goods entering the U.S. from the bloc—will be subject to a 15% tariff, according to
Novo Nordisk has named Maziar Mike…
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO.
Merck has launched a sweeping…
Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said Tuesday in its quarterly report.
AbbVie, Gilead Sciences and GSK…
AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the viruses to eliminate them as a public health problem.
Trump’s Tariffs on Medicines From Europe Stand to Cost Drugmakers Billions
Many pharmaceutical products made in Europe will face a 15 percent tariff, pinching manufacturers and potentially leading to higher drug prices.
Alfasigma has presented results…
Alfasigma has presented results from a phase 3 trial of oral JAK inhibitor Jyseleca, which has shown promise as a treatment for adults with the arthritic, inflammatory disease active axial spondyloarthritis.
After an unconventional public…
After an unconventional public display of disapproval, the FDA has made a stunning reversal on Sarepta Therapeutics’ Elevidys, recommending that Duchenne muscular dystrophy patients who can walk can start taking the gene therapy again.
Zongertinib got an accelerated…
Zongertinib got an accelerated approval for previously treated non-small cell lung cancer patients who have the relatively rare HER2 tyrosine kinase domain-activating mutations.
UnitedHealth Grew to Be a Leviathan. Then Came the Backlash.
The conglomerate was viewed as one of the most successful companies in America, but patients are enraged and investors have lost faith in its business model.
Apellis’s Empaveli is the first…
Apellis's Empaveli is the first drug to reach the IC-MPGN market and will compete against Novartis' Fabhalta with a broader label in C3G, another rare kidney disease.